Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients

HIV Clinical Trials

Volumn 9, Issue 6, 2008, Pages 367-374

  Horberg, Michael ^a   Klein, Daniel ^b   Hurley, Leo ^a   Silverberg, Michael ^a   Towner, William ^c   Antoniskis, Diana ^d   Kovach, Drew ^e   Mogyoros, Miguel ^f   Blake, William ^g   Dobrinich, Robert ^h   Dodge, Wayne ⁱ  

^a HIV Initiative   (United States)

^b HIV Infectious Disease   (United States)

^c HIV Medicine   (United States)

^d Kaiser Permanente   (United States)

^e HIV Medicine   (United States)

^f HIV Infectious Disease   (United States)

^g HIV Infectious Disease   (United States)

^h Kaiser Permanente   (United States)

ⁱ CENTER FOR HEALTH STUDIES   (United States)

Author keywords

Antiretroviral na ve; Atazanavir; Ritonavir boosting

Indexed keywords

ATAZANAVIR; DIDANOSINE; EMTRICITABINE; LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT;

EID: 62649148454     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0906-367     Document Type: Article

References (27)

1. Molina JM. Efficacy and safety of once-daily regimens in the treatment of HIV infection. Drugs. 2008;68(5):567-578.
2. Cahn PE, Gatell JM, Squires K, et al. Atazanavir - a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: Results from two randomized clinical trials. J Int Assoc Physicians AIDS Care. 2004;3(3):92-98.
3. Mobius U, Lubach-Ruitman M, Castro-Frenzel B, et al. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. J Acquir Immune Defic Syndr. 2005;39(2):174-180.
4. Nguyen ST, Eaton SA, Bain AM, et al. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus. Pharmacotherapy. 2008; 28(3):323-330.
5. Barrios A, Rendon AL, Gallego O, et al. Predictors of virological response to atazanavir in protease inhibitor-experienced patients. HIV Clin Trials. 2004;5(4):201-205.
6. Haas DW, Zala C, Schrader S, et al. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: A randomized comparative pilot trial. AIDS 2003;17(9):1339-1349.
7. Wood R, Phanuphak P, Cahn P, et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr. 2004;36(2):684-692.
8. Malan DR, Krantz E, David N, Wirtz V, Hammond J, McGrath D. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J Acquir Immune Defic Syndr. 2008;47(2):161-167.
9. Chesney M. Adherence to HAART regimens. AIDS Patient Care STDS. 2003;17(4):169-177.
10. Chesney MA, Morin M, Sherr L. Adherence to HIV combination therapy. Soc Sci Med. 2000;50(11):1599-1605.
11. NCT00084136. ACTG 5175: Once-daily PI/NNRTI therapy combinations for treatment naive, HIV infected patients in resource-limited conditions. Available at: clinicaltrials.gov
12. Kumarasamy N, Smeaton L, DeGruttola V, et al. Variation in pre-antiretroviral therapy plasma HIV-1 RNA concentrations in diverse areas of the world. In: Program and abstracts of the XVII International AIDS Conference; 2008; Mexico City, Mexico.
13. Firnhaber C, Smeaton L, Hakim J, et al. The strength of the correlation between-total lymphocyte count and CD4+ lymphocyte count varies in diverse areas of the world. In: Program and abstracts of the XVII International AIDS Conference; 2008; Mexico City, Mexico.
14. National Institute of Allergy and Infectious Diseases, National Institutes of Health. Monitoring board recommends stopping experimental treatment regimen international study of patients new to HIV treatment [bulletin]. May 27, 2008. Available at: http://www3.niaid.nih.gov/news/ news-releases/2008/ACTG_5175.htm
15. Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr. 2004;36(5):1011-1019.
16. Fairley CK, Permana A, Read TR. Long-term utility of measuring adherence by self-report compared with pharmacy record in a routine clinic setting. HIV Med. 2005;6(5):366-369.
17. Horberg MA, Hurley LB, Silverberg MJ, Kinsman CJ, Quesenberry CP. Effect of clinical pharmacists on utilization of and clinical response to antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;44(5):531-539.
18. Seguy N, Diaz T, Campos DP, et al. Evaluation of the consistency of refills for antiretroviral medications in two hospitals in the state of Rio de Janeiro, Brazil. AIDS Care. 2007;19(5):617-625.
19. Silverberg MJ, Leyden W, Horberg MA, DeLorenze GN, Klein D, Quesenberry CP Jr. Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med. 2007;167(7):684-691.
20. Krieger N. Overcoming the absence of socioeconomic data in medical records: Validation and application of a census-based methodology. Am J Public Health. 1992; 82(5):703-710.
21. California Department of Health Services, Office of AIDS. California AIDS Surveillance Report, Cumulative Cases as of December 31, 2005. Sacramento, CA: Office of AIDS; 2006.
22. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care. 2005;11(7):449-457.
23. Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care. 1988;26(8): 814-823.
24. Kitahata MM, Reed SD, Dillingham PW, et al. Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and death. Int J STD AIDS. 2004; 15(12):803-810.
25. Package insert: Highlights of prescribing information of REYATAZ (Atazanavir). Princeton, NJ: Bristol Myers Squibb. Company; 2008.
26. Bongiovanni M, Gianotti N, Chiesa E, et al. Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone. Infection. 2007;35(6):451-456.
27. Bongiovanni M, Tordato F. Tenofovir plus didanosine as NRTI backbone in HIV-infected subjects. Curr Med Chem. 2006;13(23):2789-2793.